EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Evaluation of potential drug–drug interactions with medical cannabis

Jessie Jia Yi Ho iD, Chenyi Goh iD, Caitlin Shen Ai Leong iD, Khuen Yen Ng iD, Athirah Bakhtiar iD

Clinical and Translational Science · 2024-05 · 17 (5)

DOI: 10.1111/cts.13812 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Translational Science, online erschienen am 08.05.2024. Verfasst von Jessie Jia Yi Ho und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia. Hauptthemen laut MEDLINE: Anticonvulsants, Drug Interactions, Medical Marijuana. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabis–drug interactions have caused significant concerns, mainly due to their role in the cytochrome P450 (CYP) enzyme‐mediated metabolic pathway of numerous medications. A systematic review was conducted to gain an overview of the potential interactions of cannabis with different drug classes by extracting pertinent information from published study data. From the inception of the study to October 1, 2023, we performed a systematic search of PubMed, Scopus, clinicaltrials.gov , and Web of Science. We included 54 out of 464 articles, and a total of 20 drug classes were identified to have interactions with medicinal cannabis. The cannabis–drug interactions were assessed and classified according to their probability and severity. The analysis revealed that antiepileptics had the most evidence of interaction with cannabis, followed by clobazam (CLB), warfarin, and tacrolimus. Generally, cannabis–drug interactions result in pharmacokinetic (PK) or pharmacodynamic (PD) changes. Therefore, careful monitoring should be performed to detect any unusual elevations in plasma levels. In addition, dose titrations or treatment withdrawal could help mitigate the adverse effects attributed to cannabis–drug interactions. Nevertheless, novel drugs are constantly emerging, and more research is needed to further identify potential interactions with cannabis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsDrug InteractionsMedical MarijuanaHumansClobazamWarfarin

Substanzen

AnticonvulsantsClobazamMedical MarijuanaWarfarin

Autor:innen und Institutionen

  • School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.

ORCID-Profile: Jessie Jia Yi Ho, Chenyi Goh, Caitlin Shen Ai Leong, Khuen Yen Ng, Athirah Bakhtiar

Zitieren

APA

Ho, J. J. Y., Goh, C., Leong, C. S. A., Ng, K. Y., & Bakhtiar, A. (2024). Evaluation of potential drug–drug interactions with medical cannabis. Clinical and Translational Science, 17(5). https://doi.org/10.1111/cts.13812

Vancouver

Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Evaluation of potential drug–drug interactions with medical cannabis. Clinical and Translational Science. 2024;17(5). doi:10.1111/cts.13812

BibTeX
@article{Ho2024,
  author = {Ho, Jessie Jia Yi and Goh, Chenyi and Leong, Caitlin Shen Ai and Ng, Khuen Yen and Bakhtiar, Athirah},
  title = {Evaluation of potential drug–drug interactions with medical cannabis},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {5},
  doi = {10.1111/cts.13812}
}
Kostenlos starten →